-+ 0.00%
-+ 0.00%
-+ 0.00%

Grace Therapeutics Announces Acceptance Of Abstract Highlighting Results From STRIVE-ON Phase 3 Safety Trial For Presentation At 2026 American Academy of Neurology Meeting, April 18-22

Benzinga·04/14/2026 12:12:29
Listen to the news

The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:

Session:    S21: Neurocritical Care
Date:    April 21, 2026
Time:    1:00 pm CT
Title:    Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: a Prospective, Randomized Trial